---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-030708"
form_type: "8-K"
ticker: "ARDX"
cik: "0001437402"
company_name: "ARDELYX, INC."
filed_at: "2024-07-02T23:59:59+00:00"
generated_at: "2026-05-31T23:44:52.293328+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ardelyx opts out of CMS TDAPA for XPHOZAH, foregoing add-on payment

## Summary
- Ardelyx will not apply to include XPHOZAH (tenapanor) in CMS ESRD PPS TDAPA program.
- Decision aimed at preserving patient access to the phosphate absorption inhibitor.
- By opting out, XPHOZAH will not receive transitional add-on payment from Medicare.
- Announcement made on July 2, 2024; no financial guidance provided on impact.
- Company expects to rely on standard ESRD PPS bundled payment for XPHOZAH.

## SEC filing metadata
- accession: 0001628280-24-030708
- form_type: 8-K
- ticker: ARDX
- cik: 0001437402
- company_name: ARDELYX, INC.
- filed_at: 2024-07-02T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1437402/000162828024030708/0001628280-24-030708-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1437402/000162828024030708/ardx-20240702.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-030708
- JSON: https://secwatch.observer/filing/0001628280-24-030708.json
- Plain text: https://secwatch.observer/filing/0001628280-24-030708.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.